SCHEMBL25359658

SCHEMBL25359658

CC(C)(C)OC(=O)N1CCC2(CC1)OCCc1ccc(Cl)cc12

nearest known ligand 0.45

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
ESR2 Q92731 1/20 0.45
AVPR1A P37288 3/20 0.42
STS P08842 3/20 0.42
NR1H2 P55055 1/20 0.41
USP2 O75604 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
GPR119 Q8TDV5 2/20 0.39
CYP3A4 P08684 1/20 0.39
CYP3A5 P20815 1/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
ANO1 Q5XXA6 1/20 0.39
FNTA P49354 1/20 0.38
FNTB P49356 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12701504 0.85 AVPR1A (0.55) ESR2AVPR1AUSP2SMN1; SMN2GPR119
SCHEMBL30623411 0.83 GRM5 (0.37) MEN1KMT2AESR2AVPR1ASTS
SCHEMBL2159558 0.83 AVPR1A (0.49) MEN1KMT2AESR2AVPR1ASTS
SCHEMBL4917653 0.81 MEN1 (0.48) MEN1KMT2AESR2STSNR1H2
SCHEMBL25358231 0.80 MEN1 (0.42) MEN1KMT2ASTSSMN1; SMN2ANO1
SCHEMBL1810886 0.79 OPRL1 (0.48) MEN1KMT2AESR2USP2SMN1; SMN2
SCHEMBL25359917 0.79 AVPR1A (0.41) MEN1KMT2AESR2AVPR1ANR1H2
SCHEMBL25360337 0.78 SIGMAR1 (0.48) ESR2AVPR1ANR1H2USP2SMN1; SMN2
SCHEMBL1807425 0.77 OPRL1 (0.47) ESR2AVPR1ANR1H2USP2SMN1; SMN2
SCHEMBL2493775 0.77 HSD11B1 (0.48) MEN1KMT2AESR2AVPR1ASTS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250195483-A1 SPIRO PIPERIDINE DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME VERTEX PHARMA (US) 2025-06-19 US disclosed
EP-4476207-A1 SPIRO PIPERIDINE DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME Vertex Pharmaceuticals Incorporated (US) 2024-12-18 EP disclosed
WO-2023154314-A1 SPIRO PIPERIDINE DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME VERTEX PHARMACEUTICALS INCORPORATED (US) 2023-08-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250195483-A1 SPIRO PIPERIDINE DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME APOL1, PNLIP, SAAL1 MEN1 2419/4885KMT2A 4614/4885ESR2 2506/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.